Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jul;33(4):1013-22.
doi: 10.1093/schbul/sbl057. Epub 2006 Nov 10.

Persistent negative symptoms in schizophrenia: an overview

Affiliations
Review

Persistent negative symptoms in schizophrenia: an overview

Robert W Buchanan. Schizophr Bull. 2007 Jul.

Abstract

Persistent negative symptoms represent an alternative approach for assessing negative symptoms in the context of clinical trials. Persistent negative symptoms are designed to capture those symptoms that lead to functional impairment but are currently understudied and for which there are no currently available effective treatments. Persistent negative symptoms differ from the 2 most commonly used approaches: primary, enduring negative symptoms or deficit symptoms and negative symptoms broadly defined to include negative symptoms, regardless of their etiology or duration. In contrast to deficit symptoms, persistent negative symptoms may include secondary negative symptoms. However, in contrast to negative symptoms broadly defined, the secondary negative symptoms included in the assessment of persistent negative symptoms only include those that have failed to respond to usual treatments for secondary negative symptoms. In consequence, the presence of persistent negative symptoms identifies a patient population with clinically relevant symptomatology, which is larger than the one with the deficit syndrome but less heterogeneous than that captured through the use of a nonrestrictive definition of negative symptoms. This may facilitate the selection of subjects for inclusion into research and efforts to develop new pharmacological treatments and enhance our understanding of a relevant clinical problem. Ultimately, the investigation of the different entities characterized by negative symptoms, such as persistent negative symptoms, and the enhanced understanding of their biological and clinical characteristics may help to unravel the psychopathological and biological heterogeneity of schizophrenia.

PubMed Disclaimer

References

    1. Kraepelin E. In: Dementia Praecox and Paraphrenia. Barclay RM, translator. New York, NY: RE Krieger; 1919. [Reprint 1971]
    1. Bleuler E. In: Dementia Praecox, or the Group of Schizophrenias. Zinkin J, translator. New York, NY: International Universities Press; 1908.
    1. Strauss JS. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull. 1974;11:61–69. - PubMed
    1. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? Br Med J. 1980;280:66–68. - PMC - PubMed
    1. Crow TJ. Two-syndrome concept: origins and current status. Schizophr Bull. 1985;11:471–486. - PubMed

Publication types